Myeloma Paper of the Day, May 8th, suggested by Robert Orlowski
Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day: Mass spectrometry-based assessment of M-protein in the peripheral blood from patients on phase 3 ATLAS trial during maintenance therapy may have comparable value to BM MRD assessment at the 10(-5) threshold.”
Authors: Tadeusz Kubicki, Dominik Dytfeld, David Barnidge, Dhananjay Sakrikar, Anna Przybyłowicz-Chalecka, Krzysztof Jamroziak, Pawel Robak, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Wróbel, Adam Nowicki, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Lukasz Szukalski, Agnieszka Końska, Jan Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Ken Jiang, Jennifer Cooperrider, Andrzej Jakubowiak, and Benjamin Derman.
Source: Robert Orlowski/X
Other insights by Robert Orlowski on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023